Merus Announces Data from a Phase 1/2 Study of MCLA-128 to be Presented at the 2017 American Society of Clinical Oncology Ann...
21 April 2017 - 6:05AM
UTRECHT, The Netherlands, April 20, 2017 (GLOBE
NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS), a clinical-stage
immuno-oncology company developing innovative bispecific antibody
therapeutics, today announced that data from a Phase 1/2 study of
MCLA-128 for the treatment of metastatic breast cancer will be
presented in a poster session at the American Society of Clinical
Oncology (ASCO) Annual Meeting, which will be held on June 2-6,
2017 in Chicago, Illinois.
Details of the poster presentation are as
follows:
Title: First-in-human phase
1/2 study of MCLA-128, a full length IgG1 bispecific antibody
targeting HER2 and HER3: Final phase 1 data and preliminary
activity in HER2+ metastatic breast cancer (MBC)
Abstract Number: 2522
Poster Session: Developmental
Therapeutics-Clinical Pharmacology and Experimental
Therapeutics
Date and Time: Monday, June 5, 2017, 8:00
AM-11:30 AM CT
About MCLA-128
MCLA-128 is designed to block HER3/heregulin dependent
tumor growth and survival as well as enhance immune-mediated
killing of tumors. MCLA-128 employs a 'dock and block' mechanism in
which the mode of HER2 receptor binding orientates the HER3 binding
arm to effectively block oncogenic signaling through the HER2:HER3
heterodimer even under high heregulin concentrations. In addition,
MCLA-128 is engineered for enhanced ADCC in order to recruit and
activate immune effector cells to directly kill the tumor.
About Merus N.V.
Merus is a clinical-stage immuno-oncology company
developing innovative full length human bispecific antibody
therapeutics, referred to as Biclonics®. Biclonics® are based on
the full-length IgG format, are manufactured using industry
standard processes and have been observed in preclinical studies to
have several of the same features of conventional monoclonal
antibodies, such as long half-life and low immunogenicity. Merus'
lead bispecific antibody candidate, MCLA-128, is being evaluated in
a Phase 1/2 clinical trial in Europe as a potential treatment for
HER2-expressing solid tumors. Merus' second bispecific antibody
candidate, MCLA-117, is being developed in a Phase 1/ 2 clinical
trial in patients with acute myeloid leukemia. The Company also has
a pipeline of proprietary bispecific antibody candidates in
preclinical development, including MCLA-158, which is designed to
bind to cancer stem cells and is being developed as a potential
treatment for colorectal cancer and other solid tumors, and
Biclonics® designed to bind to various combinations of
immunomodulatory molecules, including PD-1 and PD-L1.
Forward Looking
Statement
Except for the historical
information set forth herein, this press release contains
predictions, estimates and other forward-looking statements,
including without limitation statements regarding: the impact of
the collaboration on Merus' finances and clinical development,
whether any of the programs under the collaboration will be
successful; and whether and when Merus will receive any of the
expected or potential payments under the collaboration and the
amounts of such payments to Merus. These forward-looking statements
are subject to risks and uncertainties that may cause actual
results to differ materially from our expectations, including
unanticipated developments in and risks related to: research and
development efforts related to the collaboration programs; the
clinical development process, which is expensive and unpredictable;
the possibility that results of clinical trials may be unsuccessful
or insufficient to meet applicable regulatory standards or warrant
continued development; other market or economic factors;
unanticipated delays; Merus' ability to compete against parties
with greater financial or other resources; Merus' ability to
commercialize and market its products, if approved; greater than
expected expenses; and the other important factors detailed in
Merus' final prospectus filed with the Securities and Exchange
Commission, or SEC, on May 20, 2016 relating to our Registration
Statement on Form F-1, and its other reports filed with the SEC.
Merus disclaims any intent or obligation to update these
forward-looking statements. These forward-looking statements should
not be relied upon as representing Merus' views as of any date
subsequent to the date of this press release.
Contacts:
Media:
Eliza Schleifstein
+1 973 361 1546
eliza@argotpartners.com
Investors:
Kimberly Minarovich
+1 646 368 8014
kimberly@argotpartners.com
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: Merus N.V. via Globenewswire
Merus NV (NASDAQ:MRUS)
Historical Stock Chart
From Apr 2024 to May 2024
Merus NV (NASDAQ:MRUS)
Historical Stock Chart
From May 2023 to May 2024